Nika Beamon set out on a journey, and 26 doctors, 37 procedures and more than 17 years later, a rheumatologist finally ...

The FDA on Thursday gave the green light to Uplizna in IgG4-related disease, making it the first and only approved treatment for the rare and recently recognized autoimmune condition, according to ...

The FDA has approved Uplizna (inebilizumab-cdon) for the treatment of immunoglobulin G4-related disease in adult patients.

About Immunoglobulin G4-related disease (IgG4-RD) UPLIZNA is a humanized monoclonal antibody (mAb) that causes targeted and sustained depletion of key cells that contribute to underlying disease ...

The drug has become the first to receive FDA approval specifically for treating immunoglobulin G4-related disease (IgG4-RD). LAS VEGAS, April 14, 2025 /PRNewswire/ -- IgG4-related disease (IgG4-RD ...

Amgen has bagged a second indication for its B cell-depleting therapy Uplizna after the FDA cleared it for rare inflammatory disease IgG4-related disease (IgG4-RD). Acquired as part of its $27.8 ...

Amgen Inc (AMGN) reports a robust 9% revenue increase driven by key brands, despite facing pricing pressures and strategic ...

Inebilizumab significantly reduced the risk of treated and AC-determined IgG4-RD flare by 87% compared with placebo. The Food and Drug Administration (FDA) has approved Uplizna ® (inebilizumab ...

Advances Amgen's Leadership in CD19 Directed, B-Cell Depletion Therapies for Serious Autoimmune Diseases Including NMOSD, IgG4-RD and gMG IgG4-RD can occur in multiple organs and lead to fibrosis ...